Treatment options and side effects: The hormone refractory prostate cancer [Therapieoptionen und Nebenwirkungen: Das hormonrefraktäre Prostatakarzinom]

被引：0

作者：

Miller K. ^{[1
]}

机构：

[1] Urologische Klinik, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, 12200 Berlin

来源：

best practice onkologie | 2006年 / 1卷 / 1期

关键词：

D O I：

10.1007/s11654-006-0001-4

中图分类号：

学科分类号：

摘要：

[No abstract available]

引用

页码：27 / 35

页数：8

共 30 条

[21] ESC-Leitlinie 2022 onkologische KardiologieKardiovaskuläre Nebenwirkungen durch Krebstherapie verstehen und behandeln2022 ESC guidelines on cardio-oncologyUnderstanding and treating cardiovascular side effects from cancer therapy
Lars Michel
Matthias Totzeck
Tienush Rassaf
[J]. Herz, 2023, 48 (1) : 15 - 22
[22] Evaluation of the safety, pharmacokinetics and treatment effects of an ανβ3 integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases
Rosenthal, Mark A.
Davidson, Peter
Rolland, Frederic
Campone, Mario
Xue, Lingling
Han, Tae H.
Mehta, Anish
Berd, Yuliya
He, Weili
Lombardi, Antonio
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2010, 6 (01) : 42 - 48
[23] 10-Jahres-Letalität, Krankheitsprogress und behandlungsassoziierte Nebenwirkungen bei Männern mit lokalisiertem Prostatakarzinom aus der randomisierten, kontrollierten ProtecT-Studie, analysiert nach erhaltener Therapie10-Year mortality, disease progression, and treatment-related side effects in men with localized prostate cancer from the ProtecT Randomised Controlled Trial, analyzed according to treatment received
Simon K. B. Spohn
Anca-Ligia Grosu
[J]. Strahlentherapie und Onkologie, 2021, 197 (7) : 651 - 654
[24] NO CONCLUSIVE EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS (RCTS) FOR IMPROVED SURVIVAL WITH SECOND-LINE TREATMENT OPTIONS, IN PATIENTS WITH METASTATIC HORMONE-REFRACTORY PROSTATE CANCER (MHRPC) PREVIOUSLY TREATED WITH DOCETAXEL
Mason, M.
Freemantle, N.
Parnaby, A.
Hogberg, D.
[J]. VALUE IN HEALTH, 2010, 13 (07) : A254 - A254
[25] Palliative treatment of bone metastases in hormone-refractory prostate cancer: Effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels
Kawashima, Hidenori
Tanaka, Tomoaki
Kuratsukuri, Katsuyuki
Uchida, Junji
Sugimura, Kazunobu
Tamada, Satoshi
Nishisaka, Nobuyasu
Kumata, Katsuyuki
Iwai, Yoshihito
Ikemoto, Shinichi
Ezaki, Kazuyoshi
Nakatani, Tatsuya
[J]. UROLOGIA INTERNATIONALIS, 2007, 78 (04) : 345 - 350
[26] Re: Ten-Year Mortality, Disease Progression, and Treatment-Related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received
Taneja, Samir S.
[J]. JOURNAL OF UROLOGY, 2020, 203 (05): : 882 - 883
[27] NO CONCLUSIVE EVIDENCE FROM RANDOMISED CONTROLLED TRIALS TO INFORM SECOND-LINE TREATMENT OPTIONS SURVIVAL AND CLINICAL BENEFITS, IN PATIENTS WITH METASTATIC HORMONE-REFRACTORY PROSTATE CANCER (MHRPC) PREVIOUSLY TREATED WITH DOCETAXEL
Mason, M.
Freemantle, N.
Parnaby, A.
Hogberg, D.
[J]. ANNALS OF ONCOLOGY, 2010, 21 : 302 - 302
[28] Ureterstriktur nach extrakorporaler StoßwellenlithotripsieKasuistik und Übersicht über das Spektrum seltener Nebenwirkungen der modernen ESWL-TherapieUreteral stricture after extracorporeal shock wave lithotripsyCase report and overview of the spectrum of rare side effects of modern ESWL treatment
F. Finter
L. Rinnab
J. Simon
B. Volkmer
R. Hautmann
R. Kuefer
[J]. Der Urologe, 2007, 46 (7): : 769 - 772
[29] Okuläre Nebenwirkungen von Dupilumab – Übersichtsarbeit und Therapieempfehlung der „Kommission für Trockenes Auge und Oberflächenerkrankungen“ der Österreichischen Ophthalmologischen Gesellschaft (ÖOG)Ocular side effects of dupilumab—Review article and treatment recommendation by the Committee for Dry Eye and Ocular Surface Diseases of the Austrian Society of Ophthalmology (ÖOG)
Nora Woltsche
Julia Aschauer
Ingrid Boldin
Gerhard Garhöfer
Semira Kaya-Reindl
Sarah Moussa
Johannes Nepp
Stefan Palkovits
Eva Wimmer-Orlowski
Jutta Horwath-Winter
[J]. Spektrum der Augenheilkunde, 2023, 37 (5) : 131 - 137
[30] Acute Side Effects during 3-D-Planned Conformal Radiotherapy of Prostate Cancer Differences between Patient's Self-Reported Questionnaire and the Corresponding Doctor's ReportAkute Nebenwirkungen der Strahlentherapie bei 3-D-geplanter konformaler Bestrahlung des Prostatakarzinoms. Vergleich eines Patientenfragebogens und der Einschätzung durch den Arzt
Gregor Goldner
Natascha Wachter-Gerstner
Stefan Wachter
Karin Dieckmann
Monika Janda
Richard Pötter
[J]. Strahlentherapie und Onkologie, 2003, 179 (5) : 320 - 327

← 1 2 3 →